Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy

NCT02638207 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
142
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Octapharma